Skip to main content
. 2015 Jul;8(7):17–29.

TABLE 1.

Summary of studies included in pooled analysis of bimatoprost 0.03% for eyelash hypotrichosis treatment

STUDY NUMBER* AND ETIOLOGY SUBJECTS ENROLLED IN EACH GROUP, N STUDY TREATMENT DURATION MONTHS STUDY DESIGN STUDY POPULATION MEAN AGE, YEARS (RANGE)
BIM 0.03% VEH
Study 111
NCT00693420
 Idiopathic
 Postchemotherapy

137
-

141
-
4 Phase 3 R, DM, PG General (US, Canada) 49.8 (22-78)
Study 212
NCT01391273
 Idiopathic
 Postchemotherapy

87
-

85
-
4 Phase 3 R, DM, PG Japanese (Japan) 40.8 (20-68)
Study 312
NCT01391286
 Idiopathic
 Postchemotherapy

-
18

-
18
4 Phase 3 R, DM, PG Japanese (Japan) 50.6 (31-74)
Study 4
NCT00958035
 Idiopathic
 Postchemotherapy
46
-
43
-
4 Phase 4 R, DM, PG African American (US) 46.5 (19-75)
Study 5
NCT01064882
 Idiopathic
 Postchemotherapy
34
-
-
-
3 Phase 2 R, DM, AC, PG Caucasian (US) 46.3 (31-55)
BIM/BIM BIM/VEH VEH/BIM STUDY treatment duration MONTHS STUDY DESIGN STUDY POPULATION MEAN AGE, YEARS (RANGE)
Study 6[14]
NCT00907426
 Idiopathic
 Postchemotherapy
118
96
60
-
59
33
12 Phase 3 R, DM, PG General (US, Europe) 49.8 (20-76)
*

Both the study number and ClinicalTrials.gov registration number (available at www.clinicaltrials.gov) are provided.

Time of active study treatment (does not include post-treatment periods).

Study 6 was a 12-month study comprising two six-month treatment periods. For the first six months, subjects were randomized to treatment with either bimatoprost 0.03% or vehicle (treatment period 1). From Month 6 to Month 12 (treatment period 2), all subjects who received vehicle during treatment period 1 were switched to bimatoprost, whereas subjects who received bimatoprost during treatment period 1 were randomized to either continue receiving bimatoprost or switch to vehicle.

AC=active controlled; BIM=bimatoprost; DM=double masked; PG=parallel group; R=randomized; US=United States; VEH=vehicle